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KEY POINTS
 Premature neonates have a delay in the colonization of “healthy” commensal bacteria and
a propensity toward harboring pathogenic bacteria, an attribute that may be a key etiology
for the premature neonate’s increased susceptibility to develop necrotizing enterocolitis
or other infections.
 Mode of delivery does not seem to substantially alter the infant microbiome. Instead, only
formula feeding and maternal diet have lasting impacts on the infant microbiome.
 The fetus does not lie in a sterile environment. It is likely that in utero exposure to microbes
and/or a microbe’s free DNA leads to fetal immune system priming and regulation.
 Thematernaldiet isapotentmodifierofboth themother’sandthe infant’smicrobiome.Further
studies are needed to evaluate the effects of thematernal diet on the breastmilkmicrobiome.
 Dysbiosis of the maternal microbiome is currently a leading hypothesis underlying the eti-
ology of preterm birth. Therefore, further studies evaluating the microbiome can help
elucidate potential treatments for preventing preterm birth—the leading cause of death
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Valentine et al2INTRODUCTIONThe human body is host to a diverse array of largely commensal bacteria, which
collectively across all body niches comprise an individual’s personal microbiome.
The Human Microbiome Project, completed in 2012, sought to define reference
“healthy” microbiomes by evaluating and characterizing the microbiome across
multiple body sites in healthy individuals of different races and ethnicities in the
United States. Overall, this robust, multicenter study found that niche specificity,
bacterial diversity, and microbial gene carriage patterns far surpassed what was
previously thought.1–4 Importantly, commensal microbiota are more than simple by-
standers because their presence and unique metabolic processes are essential
components of our own physiology. Moreover, it is thought that the nature, state,
and composition of the microbiome are related to (and likely contribute to) the
development of several common human diseases. Dysbiosis of the human micro-
biome, defined as an aberrant microbial community, has been associated with
the development of diabetes,5–8 inflammatory bowel disease,9–13 obesity,14,15
metabolic syndrome,16 and autoimmune disorders,15,17,18–29 although causation
has yet to be established.
In keeping with the developmental origins of health and disease hypothesis,30–37 it is
thought that the role of the microbiome in disease pathogenesis likely initiates in early
life during key developmental windows, predisposing an individual to develop disease
later in life when and if exposed to the right environmental triggers. Mice raised in the
relative or complete absence of bacteria (gnotobiotic and germ-free mice) have im-
mune deficits that cannot be restored completely unless the infant and mother are
exposed to bacteria in pregnancy and early life.38,39 For these reasons, understanding
when and how the neonatal microbiome is first established, how it develops in the im-
mediate postnatal period, and what external factors (eg, mode of delivery and breast-
feeding) modify its trajectory has been a recent focus of the field.
Recent literature surrounding the perinatal microbiome has seen increased atten-
tion and focus. This article seeks to consolidate and evaluate the medical literature
assessing common perinatal interventions, their effects on the infant microbiome,
and their potential benefit to neonatal outcomes. First, pregnancy and the potential
contribution of the maternal microbiome to preterm risk as well as the neonate’s
microbiome are discussed. Second, common perinatal interventions are explored,
such as intrapartum antibiotic prophylaxis, mode of delivery, timing of delivery (prema-
ture vs term), hospitalization, and use of probiotics in both the mother and neonate.
Finally, breastfeeding versus formula feeding is discussed and the impact each may
have on neonatal outcomes.PERINATAL AND POSTNATAL INTERVENTIONS AND THEIR IMPACT ON THE NEONATAL
MICROBIOME
Although many perinatal interventions occur daily among the more than 4 million US
births annually, including the use of probiotics or intrapartum antibiotic prophylaxis
for group B streptococcus, and may seem relatively benign, the broad-reaching and
longer-term impacts are unknown (Fig. 1). By contrast, broad-spectrum microbial in-
terventions or manipulations have been studied a bit deeper and there is a bit more
known about their impact on microbial communities, their structure, and their function.
This article discusses the impact of preterm birth, common perinatal interventions,
their influence on the fetal and neonatal microbiome, and the potential short-term
and long-term neonatal outcomes.
Fig. 1. Potential influences of the developing microbiome during pregnancy and early
neonatal and infant life.
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Prematurity and the reasons leading to a preterm birth have lasting effects on both the
neonatal microbiome and both the short-term and long-term outcomes in those neo-
nates compared with delivery at term. As discussed previously, the maternal micro-
biome is essential in immune system priming of the fetus. Premature neonates are
at higher risk for infection and intestinal problems, among other illnesses, owing to
the lack of sufficient development of host tissues and immaturity of immune regulation
at birth. Further issues may relate to a lack of time for the full effects of the in utero
interactions with the maternal microbiome and/or a difference in the premature neo-
nate’s microbiome compared with the term neonate.
Thus, one key question to evaluate is, Does the microbiome differ between neo-
nates born at term compared with those born preterm? One group of investigators
from Spain evaluated 21 premature neonates’ intestinal microbiota during the first
3 months of life and compared them to term, exclusively breastfed, vaginally delivered
neonates. Premature neonates had increased levels of facultative anaerobic microor-
ganisms and decreased levels of strict anaerobes, such as Bifidobacterium,
Bacteroides, and Atopobium.40 It is difficult, however, to assess if the changes they
found are due to varying levels of gut maturity, lack of exclusive human milk feeding
(all preterm infants included in this study received mixed feeding), or other
associations with hospitalization and/or premature birth itself, for example,
antibiotics. Furthering the idea that the microbiome is different among premature
neonates compared with term neonates, other investigators have shown that
Valentine et al4very-low-birthweight neonates have decreased diversity of their microbiota, which
may be due to living in a hospital environment itself.24,41–43
Not only do premature neonates have a delay in the colonization of “healthy”
commensal bacteria, such as Bifidobacterium, but also the premature neonate’s
microbiome contains higher quantities of pathogenic bacteria and readily loses the
richness and abundance first seen at birth. Klebsiella, Weissella, Clostridium,
Enterobacteriaceae, Enterococcaceae, Streptococcaceae, and Staphylococcaceae
have all been found more commonly in premature neonates’ microbiota than in neo-
nates born at term.44 Concurrent with these results, other investigators found
increased levels of K pneumonia in the preterm infant microbiota, and C difficile
was detected exclusively in the preterm infants.40
Thus, premature neonates are more prone to foster and harbor pathogenic bacteria
rather than beneficial commensals, and the diversity and richness of their microbial
communities first seen at birth simplifies days to weeks later and after periods of often
intense interventions and isolation as well as antimicrobial therapy. This characteristic
of prematurity (or its necessary interventions) may be one key reason why this age
group has a higher likelihood of necrotizing enterocolitis (NEC) and other infectious
maladies than term neonates.
Themicrobiome of preterm infants (eg, gestational age of 23–30 weeks) varies during
the initial weeks of life, with dominance by Escherichia, Klebsiella, Enterococcus, and
Staphylococcus dominant in the gut.45 The presence of certain taxa do correlate, how-
ever, with increased gestational and postnatal age, for instance Bifidobacterium.46
Colonization by Bifidobacterium is during the initial weeks of life in preterm infants is
associated with protection from NEC47 and late-onset sepsis.48 Additional research
is needed, however, to determine is this association is causal to the prevention of these
diseases (eg, promotes gut maturation) or rather that colonization by Bifidobacterium
simply reflects a more mature gut. Nonetheless, the potential to modify the preterm in-
fant gut microbiome with probiotics is an area of active investigation. The most widely
used probiotics in preterm infants are single or combination products consisting of
Lactobacillus and Bifidobacterium. Overall, trials and meta-analyses in this area have
shown conflicting findings in terms of NEC and sepsis diagnosis. Importantly, the
receipt of probiotics results in shifts to both the gut microbiome and metabolome,
with Bifidobacterium (but not Lactobacillus) able to colonize the gut of preterm infants
long-term (even after discharge from the neonatal intensive care unit [NICU]).49
Mode of Delivery
Reported use of cesarean deliveries has been documented as early as the 1500s
although its modern usage was not pioneered and promulgated until the mid-
twentieth century after the discovery of penicillin.50 Although 40 years ago, 1 in 20
births were delivered by cesarean, to date, that figure has climbed to nearly 1 in 3
in the United States. Obstetric guidelines put forth by the American Journal of Obstet-
rics and Gynecology (AJOG) outline specific indications for cesarean deliveries to
ensure the health of the mother and her infant.51,52 Although the risks to the mother
in the immediate postoperative period and in future pregnancies are well documented,
the long-term impact of a cesarean delivery on infant health and disease is not well
understood. Numerous epidemiologic studies have inconsistently linked cesarean de-
livery with increased risk of allergy, metabolic syndrome, and obesity later in life,53,54
although given their likely multifactorial and heterogeneous nature, it has been difficult
to discern correlation versus causation.
The reported impact of cesarean delivery on the infant microbiome has been touted
as the missing link between cesarean and future disease burden, resulting from a lack
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have already begun piloting vaginal swabbing of cesarean-born infants as means of
correcting microbial community deficits. It is unclear, however, if these efforts are as
yet justifiable without clear evidence of mechanism or direct benefit in relevant animal
models.53 Furthermore, the data supporting an association between cesarean delivery
and an altered infant microbiome may be confounded by several clinical confounders,
including prematurity, antibiotic usage, andmaternal diabetes status, among others. In
a large clinical cohort of longitudinally sampled mothers and infants, the authors found
that the infant microbiome at 6 weeks of age did not vary by virtue of mode of delivery
when controlling for various clinical factors. Only formula feeding and maternal diet
seemed to have a lasting impact on the infant microbiome at this age. Therefore,
although the question of whether or not cesarean delivery has a substantial long-
term impact on the infant microbiome and ultimately in disease pathogenesis is uncer-
tain, it nevertheless remains advisable to limit the use of cesarean deliveries by
adhering to the official guidelines put forth by AJOG and other equivalent professional
societies.HUMAN BREASTMILK AND FORMULA FEEDING
The capacity to exclusive breastfeed or formula feed can have extensive effects on the
neonatal microbiome. Breast milk and formula contain different bioactive compo-
nents. For instance, formula contains macronutrients, vitamins, and a few oligosac-
charides but is absent of the highly diverse human milk oligosaccharides (HMOs).
Breast milk, however, contains macronutrients, vitamins, numerous HMOs and other
oligosaccharides, growth factors, immune cells, immunoglobulins, hormones, cyto-
kines, and a microbiome. The question becomes, Which components of human milk
alter the neonatal enteric microbiome?
At the end of the nineteenth century, the overall infant mortality in the first year of life
was as high as 30%. Medical providers noticed that breastfed infants had a higher
chance of survival and lower incidence of infectious diarrhea than formula-fed in-
fants.55 Researchers began looking at what in breast milk may be protecting these ne-
onates from increased mortality. Investigators soon found that the feces of breastfed
infants contained different bacteria from those of the bottle-fed cohort.56 In 1926,
Schonfeld57 published findings of a growth-promoting factor for Bifidobacterium
bifidus, a protective commensal, contained in breast milk. This “bifidus factor” was
later confirmed to be HMOs.58–62 Now, more than 100 different HMOs have been iden-
tified, and not every woman has the same production of HMOs.
HMOs, besides being the bifidus factor, have numerous health benefits for the
neonate. Because HMOs are resistant to the acidity of the infant stomach, they reach
the distal small intestine and colon intact and at high concentrations. Bifidobacterium
longum subsp infantis (B infantis) grows especially well when HMOs are present in the
neonatal intestine. The proliferation of B infantis helps prevent pathogenic bacteria
replicating as they compete for a limited nutrient supply. Also, B infantis is known to
produce short-chain fatty acids that favor the growth of commensals in niches that
might otherwise be colonized by potentially pathogenic bacteria.55,63 Moreover,
HMOs prevent the adhesion of viral, bacterial, and protozoan pathogens from attach-
ing to the enteric epithelium, and, thus, prevent enteric infections in the neonate.64,65
Another protective attribute of HMOs is that they serve as decoy attachment receptors
for pathogens, which can reduce infection rates.66,67 In fact, HMOs may even block
HIV entry via preventing the attachment of the virus to its entry receptor DC-SIGN,
and it may explain why mother-to-child transmission of HIV through breastfeeding is
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sure to the virus through the breastmilk.68A MOMS MATERNAL DIET, HER MICROBIOME, AND ITS POTENTIAL IMPACT ON LONG-
TERM INFANT HEALTH
The prevailing dogma indicates that the neonate is born sterile and only after delivery
is the neonate populated by bacteria. Under this belief, the French pediatrician Henry
Tissier professed in 1900, “The fetus lies in a sterile environment.”69 Both historical ev-
idence and more contemporary evidence, however, have challenged the notion of a
completely sterile intrauterine environment. In 1982, bacteria were found present in
the placenta, which began the pursuit of other researchers to determine if this was ac-
curate.70 More recently, numerous groups using both conventional culturing tech-
niques and contemporary 16S rRNA gene and/or metagenomic sequencing, have
found evidence of bacteria in association with presumed “sterile” tissues of healthy
term pregnancies, such as the placenta and amniotic fluid.71–81 Therefore, not only
may the developing fetus be exposed to bacteria earlier than believed but also detec-
tion of microbial DNA has been well established in neonates at birth as well as fetuses
and placentae prior to birth. Presumably, these microbes originate from the mother,
although the route through which these organisms can enter the intrauterine space
is not clearly established.82,83 The authors and other investigators leading this field,
however, remain uncertain if the organisms are viable or if free DNA is being detected.
Still, the observation of a nonsterile intrauterine environment by metagenomic and
other measures indicates that the contribution of the maternal microbiome in preg-
nancy may be as important to the neonatal microbiome as the immediate postnatal
period.
Evidence of the Maternal Microbiome Influencing Neonatal Development
The role of maternal exposures and the maternal microbiome in the community and
functional establishment of the infant microbiome may also influence immune reper-
toire and functional development. To test this hypothesis, one study evaluated the
impact of the maternal microbiome on the intestinal immune system development
of the offspring. Gomez de Aguero and colleagues84 devised an experiment in which
germ-free pregnant mice were transiently colonized with a genetically engineered
form of Escherichia coli, which does not persist in the murine intestine. The pregnant
mice that were transiently colonized gave birth to pups who had increased intestinal
innate lymphoid cells and mononuclear cells compared with controls. In addition,
these same researchers further looked into the effects of maternal antibodies and
maternal microbial molecular transfer on the priming of the fetal immune system.
They found that the maternal microbiome and maternal antibodies promote transfer
of noninfective microbial molecules to the fetus. These microbial molecules are
believed to prime the neonatal innate immune system and prepare the fetus for the
postnatal inundation of microbes that eventually colonize the neonatal intestine.84
Thus, microbes are essential in priming the fetal immune system and preparing the
fetus against the plethora of pathogens it will soon encounter after birth (Fig. 2).
The Impact of the Maternal Diet and Health on the Early Neonatal Microbiome
The maternal microbiome fluctuates throughout gestation and is associated with
obesity, altered caloric density, and content of diet, and comorbidities, such as gesta-
tional diabetes. Emerging evidence suggests that many of these factors are associ-
ated with differences in the early neonatal microbiome, suggesting that the state of
Fig. 2. Evidence from rodent studies suggesting the importance of microbes during gesta-
tional development for metabolic and immune health among offspring.
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transmitted to the neonate and how amicrobiome ultimately develops. Diet is a potent
modifying factor of the adult gut microbiome and consequently, in both animal models
and human cohorts, the composition of the maternal diet in pregnancy is associated
with distinct changes in the immediate neonatal gut microbiome as well.83,85–87 In the
Japanese macaque, a neonate born to a mother consuming a relatively high-fat diet in
pregnancy was associated with a depletion of commensal species like Campylo-
bacter, whereas in humans a maternal high-fat diet was associated with lower levels
of Bacteroides species.83,87 Work in animal models has demonstrated that
commensal enteric species, in particular Bacteroides, are vital for normal gut immune
development; therefore, lacking these beneficial microbes during this early develop-
mental window is hypothesized to have a lasting effect on the neonate, ultimately pre-
disposing the infant to atopy and other autoimmune disorders later on in life.88–90
The effect of maternal diet seems to extend beyond gestation. Research has shown
that a high-fat diet leads to increased milk fat concentration and content compared
with a high-carbohydrate diet.91 No differences in milk production or quantity of
milk, however, were observed. Therefore, neonates consuming breast milk from
mothers with a high-fat diet consume higher energy intake, which can have potential
effects on the development of their microbiome. Although it has not been studied, dif-
ferences in the properties of the breastmilk likely affect which bacteria flourish in the
neonatal microbiome, but further studies are needed to confirm this hypothesis. Along
these same lines, the maternal diet may be associated with alterations in the breast
milk microbiome. Unfortunately, there currently are no studies published evaluating
this association. Investigations are currently exploring this hypothesis and will help un-
derstand any substantial impact the diet has on the breastmilk microbiome.
Maternal chronic conditions, such as gestational diabetes, overweight status, and
obesity, are now known to have associated changes in the maternal microbiome. Bas-
sols and colleagues92 showed that women with gestational diabetes have a distinct
placental microbiota profile, which includes a lower abundance of Acinetobacter,
which was associated with higher glucose concentrations and a more proinflamma-
tory maternal phenotype. In another study, Gomez-Arango and colleagues93 evalu-
ated the relationship between the enteric microbiome and metabolic hormones in
overweight and obese pregnant women. Elevations of specific hormones, such as in-
sulin, adipokine, and glucose-dependent insulinotropic polypeptide, were associated
with elevations or reductions of specific bacteria. These results suggest that the
enteric microbiome may have the potential to influence metabolism of the pregnant
Valentine et al8woman. The impact that these chronic conditions have on the fetus and neonate has
not been extensively studied and is still open for investigation.
Antibiotic Administration
As discussed previously, the maternal microbiome potentially helps maintain preg-
nancy. Antibiotics disrupt and alter the microbiome. Thus, it is a natural progression
of this thought that antibiotics and their effects on the microbiome can affect not
only the mother but also the fetus. Antibiotics account for a majority of prescribed
medications during pregnancy. One large Danish study showed that 51% of women
had received 3 or more courses of antibiotics in the 4 years before, during, and after
pregnancy.94 In another study, maternal antibiotic administration was associated with
a 30% increased risk of the offspring developing asthma.94 Also, antibiotic usage in
the pregnant woman has been linked to higher rates of neonatal illnesses, such as
NEC, and increased rates of cerebral palsy and developmental delay.95,96
Further investigating the role of antibiotics on thematernal microbiome and neonatal
outcomes, a murine model was devised. Pregnant, nonobese diabetic mice were
given antibiotics. The offspring were observed to have immunologic changes in their
intestines compared with those that did not receive antibiotics prenatally.97 Further-
more, in humans, antibiotics during pregnancy alter the vaginal microbiome, which
then lead to changes in the colonization and development of the neonatal
microbiome98 as well as an association with increased childhood obesity99 and
asthma.94,100,101
A systematic review published in 2013 showed that prophylactic antibiotics during
the second or third trimesters in mothers with intact membranes do not decrease
adverse outcomes and morbidity in pregnancy.102 Also, even short-term antibiotic
administration can have long-standing effects on the microbiome with possible asso-
ciated changes in the immune system. In another study of 198 healthy term infants,
maternal intrapartum antibiotic prophylaxis and birth method were documented.
The infant gut microbiota was significantly different with intrapartum antibiotic prophy-
laxis exposure with persistence of the differences up to 12 months of age, with the
findings found in both caesarean and vaginal deliveries.103 An increase in pathogenic
bacteria, such as Enterococcus and Clostridium, were over-represented at 3 months
after the maternal intrapartum antibiotic prophylaxis. These findings support that an-
tibiotics, even if for a short course, such as with intrapartum antibiotic prophylaxis, do
have long-lasting effects on not only on the mother but also the neonate.
What, however, is the impact of antibiotics given directly to the neonates directly af-
ter birth, such as for early onset sepsis, on the neonatal microbiome? Premature ne-
onates almost universally receive antibiotics at some point in their stay in the NICU,
many in the first days of life. Gibson and colleagues104 evaluated the impact of
neonatal antibiotics on the development of antibiotic resistance, species diversity,
and the prevalence of pathogenic bacteria predominating the neonatal microbiome.
They found that antibiotics significantly decreased species richness and diversity in
the intestinal microbiome.104 In addition, multidrug-resistant bacterial members of
the genera Escherichia, Klebsiella, and Enterobacter predominated the premature
neonatal gastrointestinal microbiota.104
Brooks and colleagues105 found in a separate study that bacteria from the neonate’s
surroundings in the NICUmay be directly inoculated into the neonate and be the source
of the pathogenic bacteria. For example, one infant had K pneumonia detected in the
room on day of life 3, and it was then detected in the neonate’s gut on day of life
9.105 Staphylococcus epidermidis, K pneumoniae, Bacteroides fragilis, and E coli
were found widely distributed throughout the rooms of the neonates, and they are all
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predisposition for these pathogenic colonizers due to the lack of time in utero, which
helps facilitate the gut immune priming and development? Could early use of antibiotics
predispose these neonates to these pathogens? Or, is it just simply living in the hospital
environment? Likely, it is a combination of these factors, but further research is currently
exploring these and other questions. Regardless, antibiotics given intrapartum as well
as postpartum have direct effects on the neonatal microbiome.THE MICROBIOME AND PRETERM BIRTH: FRIEND OR FOE?
Preterm birth is the leading cause of death among children under the age of 5 years old
throughout the world, although its etiology is poorly understood and effective preven-
tion and treatment options are lacking.106 Although heterogeneous in nature, preterm
birth is hypothesized to have an infectious etiology. A pathogenic organism, however,
has yet to be attributed to preterm birth whereas antibiotic usage for a presumptive
infection has not been shown to provide benefit.107,108 The emergence of microbiome
science applied to human health has led to the hypothesis that community level
changes to the maternal microbiome is contributory to premature labor, rather than
by infection of a specific microbe.109 As such, efforts to characterize the “healthy”
maternal microbiome of the vagina and other body sites has been prioritized, with
the intent of identifying patterns of deviation associated with preterm birth risk.
During pregnancy, a woman’s body undergoes both physical and hormonal
changes across nearly every organ system to support fetal development, ready for
parturition, and prepare for lactation in the postnatal period. Similarly, the maternal
microbiome undergoes complementary rearrangements that are believed beneficial
(a more thorough review of these changes can be found by Chu and colleagues110).
The most notable of these changes with respect to preterm birth risk is the observation
that in healthy pregnancies, the overall diversity of the vaginal microbiome tends to
decrease into the third trimester, with Lactobacillus species tending to become the
dominant member.111 Within the vaginal milieu, lactobacillus species are believed to
provide a natural defense against pathogenic overgrow within the vaginal canal by
maintaining a low vaginal pH and may potentially explain the longstanding association
of bacterial vaginosis with preterm birth.112–115
For these reasons, aberrant microbial communities, otherwise known as dysbiosis,
in the vaginal microbiome has been hypothesized to contribute to premature labor,
potentially by promoting proinflammatory cytokines that can be stimulated by such
a derangement of the microbial milieu. There are conflicting data, however, on whether
the vaginal microbiome has a characteristic profile that reliably predicts preterm
birth.116,117 Romero and colleagues117 reported that the bacterial composition and
abundance did not differ between mothers who delivered preterm compared with
those who delivered at term whereas, conversely, DiGiulio and colleagues116 reported
that reduced Lactobacillus and increased Gardnerella or Ureaplasma were associated
with increased risk of preterm birth. The discrepancy between these studies may be in
part confounded by the known variation of the vaginal microbiome throughout preg-
nancy, which is characterized by enrichment of Lactobacillus with increasing gesta-
tional age, reduced overall richness and diversity, and greater overall stability.116,117
Alternatively, ethnic and racial differences between the 2 cohorts may account for
the differences seen between these studies, but this has yet to be accounted for in
the current literature.
The uncertain association between the vaginal microbiome and preterm birth has
spurred investigation into the microbial communities of other body sites, including
Valentine et al10the mouth, the gut, the placenta, and the intrauterine environment. Within the gut,
Shiozaki and colleagues118 found that the fecal microbiota had significantly higher
levels of Clostridium and reduced levels of Bacteroides in women who had a preterm
birth, although the impact of such changes to preterm labor is unknown.118 Other
intriguing studies have shown that the placental microbiome, which most closely re-
sembles the oral microbiome, is altered in cases of preterm birth, whereas amniotic
fluid collected in women who have preterm birth harbor bacteria from the oral cavity.
These observations have been intriguing considering that periodontal disease is asso-
ciated with a 7-fold increased risk of preterm birth.119 Periodontal disease may lead to
hematogenous spread of bacterial pathogens to the placenta and the fetus, disrupting
the placental microbiome and ultimately leading to premature labor, although further
studies in controlled animal models are needed evaluate this potential mechanism.
A microbiome-centric perspective has the potential to innovate the way in which in-
terventions for preterm birth prevention are developed and administered. Traditionally,
for microbe-related disorders, antibiotic regimens are given to kill the pathogenic or-
ganisms. In the context of preterm birth, however, such efforts have shown ineffective
or even increase risk of preterm birth. Treatments targeting bacterial vaginosis during
pregnancy did not prevent preterm birth in multiple studies and increased risk in
others.120–122 A 2012 Cochrane review demonstrated that treatment can eradicateTable 1
Table of key topics in relationship to neonatal microbiome research and key associated articles
Topic Key References Pertaining to Topic
Preterm delivery and effects
on neonatal microbiome
Arboleya et al,40 2012; Schwiertz et al,24 2003; Magne
et al,41 2006; Roudie`re et al,42 2009; Rouge´ et al,43 2010;
Morowitz et al,44 2011; Stewart et al,45 2017; Butel et al,46
2007; Stewart et al,47 2016; Stewart et al,48 2017;
Abdulkadir et al,49 2016
Mode of delivery and neonatal
microbiome
Boley et al,50 1991; Aagaard et al,53 2016; Yuan et al,54 2016;
American College of Obstetricians and Gynecologists,51,52
2014
Breastmilk and formula feeding
and neonatal microbiome
Bode,55 2012; Gauhe et al,58 1954; Gyorgy et al,59–61 1954;
Rose et al,62 1954; Gibson & Wang,63 1994; Kunz et al,64
2000; Newburg et al,65 2005; Simon et al,66 1997;
Gustafsson et al,67 2006
Maternal diet and neonatal
microbiome
Ma et al,83 2014; David et al,85 2014; Gohir et al,86 2015;
Chu et al,87 2016; Troy & Kasper,88 2010; Round &
Mazmanian,89 2010; Mazmanian et al,90 2005;
Mohammad et al,91 2009; Bassols et al,92 2016;
Gomez-Arango et al,93 2016
Antibiotics and neonatal
microbiome
Stokholm et al,94 2014; Kenyon et al,95 2001; Kenyon et al,96
2008; Tormo-Badia et al,97 2014; Stokholm et al,98 2014;
Mueller et al,99 2015; Vidal et al,100 2013; Jepsen et al,101
2003; Flenady et al,102 2013; Azad et al,103 2016;
Gibson et al,104 2016; Brooks et al,105 2014
Microbiome and birth
associations
Brocklehurst et al,107 2013; Oliver & Lamont,108 2013;
Baldwin et al,109 2015; Chu et al,110 2016; Aagaard et al,111
2012; Litich et al,112 2003; McDonald et al,113 1991;
Romero et al,114 2002; Hay et al,115 1994; Offenbacher
et al,116 1996; Nygren et al,117 2008; McDonald et al,118
2007; Thinkhamrop et al,119 2015; Schwiertz et al,15 2010;
Koren et al,16 2012
Maternal-Infant Microbiomes and Neonatal Outcomes 11bacterial vaginosis but does not have any significant impact on the prevention of pre-
term birth or preterm prelabor rupture of membranes. Therefore, it is not recommen-
ded to screen and treat all pregnant women with bacterial vaginosis to prevent
preterm birth or preterm premature rupture of membranes.107
Ultimately, therapies aimed at preventing preterm birth may focus on maintaining
healthy communities, rather than treating for specific pathogens. Before such treat-
ment approaches are realized, however, additional work is needed to evaluate the
impact of the maternal microbiome across different body niches, inclusive of the
mouth, the vagina, and the intrauterine environment.
SUMMARY
Overall, perinatal interventions have significant impact on both the maternal and
neonatal microbiomes (Table 1 lists references per topic). Some key questions, how-
ever, are still left unanswered. Does dysbiosis of the enteric microbiome play a larger
role in the development of preterm birth? If so, are there any therapies that can be tar-
geted to ameliorate this dysbiosis and protect against preterm birth? There is limited
research evaluating the impact of antenatal steroids on the fetal and/or neonatal
microbiome. How do antenatal steroids affect the maternal, fetal, and neonatal micro-
biomes? Finally, it is known that microbial contact begins in utero, but is this true colo-
nization or just transient seeding? Because it is virtually impossible to ascertain this
fact in human experiments, future investigations in animal models are imperative to
help determine if it is truly colonization or simply a transient seeding that has an impact
on the fetus. These and other questions are now imperative for researchers to
address, to evaluate and further the understanding of the microbiome, its develop-
ment, and its potential interactions on the development of disease states in the
host. Through this understanding, potential directed therapies can be initiated, which
could lead to improvements in neonatal outcomes throughout the world.
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